Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline
- PMID: 18199038
- DOI: 10.1086/526775
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline
Abstract
Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.
Comment in
-
Tigecycline for Acinetobacter baumannii infection: other considerations.Clin Infect Dis. 2008 Jun 1;46(11):1797-8; author reply 1798-9. doi: 10.1086/588051. Clin Infect Dis. 2008. PMID: 18462123 No abstract available.
-
Correction of a reference to clinical laboratory standards institute interpretive criteria.Clin Infect Dis. 2008 Jun 1;46(11):1798; author reply 1798-9. doi: 10.1086/588056. Clin Infect Dis. 2008. PMID: 18462124 No abstract available.
-
Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline.Clin Infect Dis. 2008 Jun 15;46(12):1932-3. doi: 10.1086/588557. Clin Infect Dis. 2008. PMID: 18540810 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
